New anticoagulants in critical care settings

Area of Science:

• Critical care medicine
• Pharmacology
• Hematology

Background:

• Thromboembolic events are prevalent in critically ill patients, contributing to significant morbidity and mortality.
• Antithrombotic agents are crucial for preventing and treating venous thromboembolism and for stroke prevention in various conditions.
• Established antithrombotics include aspirin, clopidogrel, vitamin K antagonists, and fondaparinux.

Purpose of the Study:

• To review the clinical application of novel oral anticoagulants in intensive care unit (ICU) settings.
• To highlight studies on dabigatran, rivaroxaban, and apixaban in critically ill populations.

Main Methods:

• Literature review of studies focusing on new oral anticoagulants in intensive care.
• Analysis of clinical development phases and availability of dabigatran, rivaroxaban, and apixaban.

Main Results:

• New small-molecule, selective Factor Xa and thrombin inhibitors are gaining attention.
• Dabigatran, rivaroxaban, and apixaban are in advanced clinical development and available in some regions.
• This review specifically focuses on their use within the intensive care environment.

Conclusions:

• Novel oral anticoagulants represent a significant advancement in antithrombotic therapy.
• Further research and clinical experience are needed to fully establish the role of these agents in intensive care.
• Understanding the efficacy and safety of dabigatran, rivaroxaban, and apixaban in critically ill patients is essential.